医学部 消化器内科学

橋本 千樹

ハシモト センジュ  (senju hashimoto)

基本情報

所属
藤田医科大学 医学部 医学科 消化器内科学 臨床教授
学位
博士(医学)

J-GLOBAL ID
201501020246836172
researchmap会員ID
7000012760

主要な研究キーワード

 3

論文

 463
  • Eizaburo Ohno, Teiji Kuzuya, Naoto Kawabe, Kazunori Nakaoka, Hiroyuki Tanaka, Takuji Nakano, Kohei Funasaka, Ryoji Miyahara, Senju Hashimoto, Yoshiki Hirooka
    DEN open 5(1) e413 2025年4月  
    The new Kyoto guidelines for the management of intraductal papillary mucinous neoplasm (IPMN) provide evidence-based recommendations for the diagnosis and treatment of IPMN. Endoscopic ultrasonography (EUS) is a diagnostic modality with a high spatial resolution that allows detailed observation and obtaining cyst fluid or tissue samples via EUS-guided fine needle aspiration (EUS-FNA). Currently, EUS is an indispensable examination method for the diagnosis of pancreatic diseases. On the other hand, there have been concerns that EUS imaging tends to be highly operator-dependent, and may lack objectivity. Previous guidelines have assigned EUS as an option for patients with worrisome features. However, recent reports indicate that the sensitivity of EUS for the diagnosis of mural nodules (MNs) is more than 90%, comparable or superior to that of contrast-enhanced computed tomography or magnetic resonance cholangiopancreatography. The specific advantages of EUS in the diagnosis of IPMN are: (1) high spatial resolution imaging for the diagnosis of MNs, (2) contrast-enhanced EUS for differentiation of intra-cystic MNs from mucous clots, and (3) pathological diagnosis using EUS-FNA and differential diagnosis of a pancreatic cystic tumor by cystic fluid analysis. In order to utilize EUS in the diagnosis of IPMN, endoscopists are required to have the skills to provide sufficiently objective imaging findings.
  • Kazunori Nakaoka, Eizaburo Ohno, Kento Kuramitsu, Teiji Kuzuya, Kohei Funasaka, Takumi Tochio, Tadashi Fujii, Hideaki Takahashi, Nobuhiro Kondo, Ryoji Miyahara, Senju Hashimoto, Yoshiki Hirooka
    Nutrients 16(17) 2889-2889 2024年8月29日  
    Less than half of all patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) respond to chemotherapy, and the prognosis of PDAC is poor, which may be mediated by the gut microbiota. We investigated the clinical improvement effects of 1-kestose, a fructooligosaccharide, on PDAC chemotherapy in this single-center, randomized, controlled pilot trial conducted at Fujita Health University Hospital, which enrolled patients with PDAC. The trial included 1-kestose administration and non-administration groups. The 1-kestose group received 9 g of 1-kestose daily for 12 weeks, and their blood markers, imaging studies, physical findings, and gut microbiota were evaluated. In the 1-kestose administration group, the cancer marker CA19-9 significantly decreased, and there was a reduction in the neutrophil-to-lymphocyte ratio (NLR). There was also suppression of the reduction of albumin levels and of an increase in C-reactive protein. Additionally, Escherichia coli, which typically increases in PDAC, significantly decreased in the 1-kestose group. Thus, 1-kestose altered the gut microbiota and improved the prognostic factors for PDAC. Large-scale, long-term trials of 1-kestose interventions for PDAC are thus warranted to improve the prognosis of PDAC.
  • Eizaburo Ohno, Teiji Kuzuya, Naoto Kawabe, Kazunori Nakaoka, Hiroyuki Tanaka, Takuji Nakano, Yohei Miyachi, Senju Hashimoto, Yoshiki Hirooka
    Journal of medical ultrasonics (2001) 2024年7月11日  
  • 田中 浩敬, 大野 栄三郎, 葛谷 貞二, 中岡 和徳, 中野 卓二, 川部 直人, 宮原 良二, 橋本 千樹, 廣岡 芳樹
    超音波医学 51(Suppl.) S180-S180 2024年4月  
  • Eizaburo Ohno, Teiji Kuzuya, Naoto Kawabe, Kazunori Nakaoka, Hiroyuki Tanaka, Takuji Nakano, Yohei Miyachi, Senju Hashimoto, Yoshiki Hirooka
    Journal of medical ultrasonics (2001) 51(2) 227-233 2024年4月  
    Endoscopic ultrasonography (EUS) provides high spatial resolution and more detailed images than other diagnostic modalities. Furthermore, EUS-guided tissue acquisition (EUS-TA), such as EUS-guided fine needle aspiration or biopsy (EUS-FNA/FNB), is an indispensable tool in pancreaticobiliary disease diagnostics, supporting a conclusive pathological diagnosis. In this review, we evaluate the current status and the usefulness of EUS-TA for the diagnostics of the following biliary tract diseases: (A) biliary stricture diagnostics, (B) biliary tract cancer (BTC) itself, and (C) staging of advanced BTC. Previous reports have shown that EUS-FNA for biliary lesions is a safe procedure that is useful in differentiating biliary cancer from benign lesions and in the staging of BTC. On the other hand, the diagnostic performance of EUS-TA for bile duct lesions is reported to be similar to that of transpapillary biopsy. Overall, EUS-TA for biliary lesions may be a safe and effective method, but it should be performed with an understanding of the risk of serious adverse events such as bile leakage and peritoneal dissemination of cancer. It is recommended for distal biliary stricture lesions for which endoscopic retrograde cholangiopancreatography cannot confirm the diagnosis or gallbladder lesions if they do not require the needle to pass through the biliary lumen.

MISC

 117

講演・口頭発表等

 98

共同研究・競争的資金等の研究課題

 2

その他教育活動上特記すべき事項

 6
  • 件名
    第23回医学教育ワークショップ
    終了年月日
    2008/05/17
    概要
    「CBT試験問題作成」に参加した。
  • 件名
    第25回医学教育ワークショップ 
    終了年月日
    2008/09/06
    概要
    「卒業試験臨床長文問題ブラッシュアップ」に参加した。
  • 件名
    第27回医学教育ワークショップ 
    終了年月日
    2009/04/12
    概要
    「小グループ学習の充実」に参加した。
  • 件名
    第30回医学教育ワークショップ 
    終了年月日
    2009/08/29
    概要
    「計算問題 多肢選択問題 臨床長文問題ブラッシュアップ」に参加した。
  • 件名
    第33回医学教育ワークショップ 
    終了年月日
    2010/05/15
    概要
    「CBT試験問題作成」に参加した。
  • 件名
    第35回医学教育ワークショップ
    終了年月日
    2010/08/28
    概要
    「多肢選択問題 臨床長文問題ブラッシュアップ」に参加した。